Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...

Diabetes: Symptoms, Diagnosis, and Complications

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is based on...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

Type II Diabetes II: Pathophysiology

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Isolation and characterization of mesenchymal stem cells from caprine umbilical cord tissue matrix.

Tissue & cell·2016

Same author

Secretome Cues Modulate the Neurogenic Potential of Bone Marrow and Dental Stem Cells.

Molecular neurobiology·2016

Same author

Long-circulatory nanoparticles for gemcitabine delivery: Development and investigation of pharmacokinetics and in-vivo anticancer efficacy.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2016

Same author

Influence of immobilization and forced swim stress on the neurotoxicity of lambda-cyhalothrin in rats: Effect on brain biogenic amines and BBB permeability.

Neurotoxicology·2016

Same author

Isolation and characterization of alborixin from Streptomyces scabrisporus: A potent cytotoxic agent against human colon (HCT-116) cancer cells.

Chemico-biological interactions·2016

Same author

Pragmatic use of insulin degludec/insulin aspart co-formulation: A multinational consensus statement.

Indian journal of endocrinology and metabolism·2016

Search research articles

Related Experiment Video

Updated: Jul 10, 2026

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Published on: April 7, 2023

Risk of Dementia in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus DPP-4 Inhibitors: A Systematic Review

Kiran Kumari¹, Anusha Bai², Fnu Geeta²

¹Ziauddin Medical University, Karachi, Pakistan.

Endocrinology, Diabetes & Metabolism

|March 4, 2026

Summary

Sodium-glucose cotransporter-2 (SGLT2) inhibitors significantly lower dementia risk in type 2 diabetes mellitus patients compared to dipeptidyl peptidase-4 (DPP-4) inhibitors. This finding suggests potential neuroprotective benefits of SGLT2 inhibitors.

More Related Videos

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

Related Experiment Videos

Last Updated: Jul 10, 2026

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Published on: April 7, 2023

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

Area of Science:

Endocrinology
Neurology
Pharmacology

Background:

Type 2 diabetes mellitus (T2DM) is a known risk factor for dementia.
The cognitive impact of glucose-lowering therapies is not fully understood.
Sodium-glucose cotransporter-2 (SGLT2) inhibitors may offer neuroprotection over dipeptidyl peptidase-4 (DPP-4) inhibitors.

Purpose of the Study:

To compare the risk of incident dementia in T2DM patients initiating SGLT2 inhibitors versus DPP-4 inhibitors.
To investigate the association between SGLT2 inhibitors and dementia risk.
To evaluate the impact of glucose-lowering therapies on cognitive decline.

Main Methods:

Systematic literature search of PubMed, Scopus, and Cochrane Central Register through June 1, 2025.
Primary outcome: all-cause dementia; Secondary outcomes: Alzheimer's disease, vascular dementia.
Random-effects models used to pool adjusted hazard ratios (HRs); subgroup analyses conducted.

Main Results:

Nine retrospective cohort studies included 2,433,086 individuals.
SGLT2 inhibitors associated with significantly lower risk of all-cause dementia (HR=0.74), Alzheimer's (HR=0.62), and vascular dementia (HR=0.54) versus DPP-4 inhibitors.
Dapagliflozin and empagliflozin showed benefit; canagliflozin did not. Findings consistent across age and sex subgroups.

Conclusions:

SGLT2 inhibitors are linked to reduced dementia risk in T2DM patients compared to DPP-4 inhibitors.
Potential neuroprotective effects of SGLT2 inhibitors warrant further investigation.
Prospective trials are needed to confirm findings and elucidate mechanisms.